Century Therapeutics, Inc. last reported quarterly results on Aug 12, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): diluted EPS of -$0.17. It usually reports 43–71 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 12, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 13, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 43–71 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 12, 2026
43 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-35
-6.2%
|
-0.17
+55.3%
|
|
May 13, 2026
43 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-22
-128.3%
|
-0.11
-112.4%
|
|
Mar 12, 2026
71 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
0
-100.0%
|
-19
+46.9%
|
-0.22
+47.9%
|
|
Nov 13, 2025
44 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
109
+13700.8%
|
-34
-10.2%
|
-0.40
-8.1%
|
|
Aug 14, 2025
45 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
0
-100.0%
|
-33
-4.3%
|
-0.38
+0.0%
|
|
May 15, 2025
45 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
109
+12667.7%
|
77
+372.8%
|
0.89
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
4
+1457.1%
|
-36
+8.4%
|
-0.42
+35.6%
|
|
Nov 5, 2024
36 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
1
+434.5%
|
-31
+4.6%
|
-0.37
+32.7%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IPSC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Philadelphia, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1850119
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.